Search the Newsreel

147,000 Shares in ImmunityBio, Inc. $IBRX Purchased by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. acquired 147,000 shares of ImmunityBio, Inc. (IBRX) during the second quarter, valued at approximately $1.29 million. Institutional investors now hold 8.58% of the company, while corporate insiders own 66.10%, despite recent insider selling totaling about $3.92 million. ImmunityBio reported a …

CSTL (CSTL) insider and family trusts detail planned and recent stock sales

A recent SEC Form 144 filing indicates a planned sale of 25,792 shares of CSTL common stock, valued at $763,959.04, by an insider and related family trusts, to be executed around August 14, 2026, through Goldman Sachs & Co. LLC. The filing also details …

354,395 Shares in BioAge Labs, Inc. $BIOA Bought by Walleye Capital LLC

Walleye Capital LLC recently acquired 354,395 shares of BioAge Labs, Inc. (NASDAQ:BIOA) for approximately $8.7 million, representing 0.8% of the company. Other institutional investors also increased their stakes in the clinical-stage biotech firm. Analysts have a "Moderate Buy" consensus rating with an average price …

Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA

Walleye Capital LLC has acquired a new stake of 347,898 shares in Tyra Biosciences, Inc. (NASDAQ:TYRA), valued at approximately $11.1 million, bringing institutional ownership in the company to 84.14%. Despite the stock opening at $25.29, well below its 52-week high, analysts maintain a "Moderate …

Krystal Biotech (KRYS) Director Dino Rossi Sells 25,000 Shares

Krystal Biotech (KRYS) Director Dino Rossi sold 25,000 shares of the company on August 14, 2026, for approximately $8.23 million, reducing his direct ownership to 50,000 shares. This sale continues a trend of insider selling over the past year, with no insider buys reported, …

Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA

Walleye Capital LLC has acquired 386,183 shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the second quarter, a new stake valued at approximately $14.4 million. This purchase represents 0.44% of IDEAYA Biosciences. Despite a reported quarterly loss of $1.22 per share, institutional ownership of the …

Forte Biosciences, Inc. (NASDAQ:FBRX) Given Average Recommendation of "Hold" by Brokerages

Forte Biosciences, Inc. (NASDAQ:FBRX) has received an average "Hold" rating from seven brokerages, with an average 12-month price target of $72.50, below its current $76.83 stock price. Recent analyst coverage has generally been negative, including downgrades from Wall Street Zen, Weiss Ratings, Barclays, and …

BioNexus Gene Lab Corp (BGLC) CEO reports 338,709-share award and 11.5% stake

BioNexus Gene Lab Corp (BGLC) CEO Su-Leng Tan Lee was granted 338,709 shares as a fully vested Other Stock-Based Award under the company’s 2025 Equity Incentive Plan for completed services. This award gives her beneficial ownership of approximately 11.5% of the outstanding common stock, …

Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Average Recommendation of "Moderate Buy" by Brokerages

Assembly Biosciences (NASDAQ:ASMB) has received an average "Moderate Buy" recommendation from brokerages, with five out of seven analysts rating the stock a buy. The average 12-month price target for ASMB is $44.00, significantly higher than its recent price of $32.95. The company also reported …

NewEdge Advisors LLC Trims Position in Biogen Inc. $BIIB

NewEdge Advisors LLC significantly reduced its stake in Biogen Inc. by 38.1% in the first quarter, selling 8,017 shares and retaining 13,031 shares valued at $2.39 million. Despite this, institutional investors still collectively own 87.93% of Biogen. The biotechnology company recently surpassed analyst expectations …

Wedge Capital Management L L P NC Buys Shares of 128,845 Theravance Biopharma, Inc. $TBPH

Wedge Capital Management L L P NC recently acquired 128,845 shares of Theravance Biopharma (NASDAQ:TBPH) worth approximately $2.19 million, now owning about 0.25% of the company. Institutional investors hold 99.10% of TBPH, despite the company reporting an adjusted loss and missing revenue expectations in …

Gufic Biosciences Q1 Results: Net profit up 23% YoY to ₹80 crore

Everett Harris & Co. CA Invests $2.55 Million in Zimmer Biomet Holdings, Inc. $ZBH

Everett Harris & Co. CA recently acquired a new stake of 29,647 shares, valued at approximately $2.55 million, in Zimmer Biomet Holdings, Inc. during the second quarter. Other institutional investors have also adjusted their holdings in ZBH, which currently has 88.89% institutional ownership. Zimmer …

Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen has downgraded Fortress Biotech (NASDAQ:FBIO) from a "strong-buy" to a "hold" rating. The stock currently holds an average "Hold" rating among analysts with a consensus price target of $17.00. Fortress Biotech recently reported stronger-than-expected quarterly earnings, with EPS of -$0.08 and …

IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend

California State Teachers Retirement System Purchases 21,011 Shares of MBX Biosciences, Inc. $MBX

The California State Teachers Retirement System significantly increased its stake in MBX Biosciences by 1,197.9%, now holding 22,765 shares valued at $680,000. Other institutional investors also raised their positions in the company. Despite the company missing its Q2 earnings estimates, analysts maintain a "Moderate …

Dimensional Fund Advisors LP Invests $1.40 Million in MBX Biosciences, Inc. $MBX

Dimensional Fund Advisors LP has acquired a new stake worth $1.40 million in MBX Biosciences, Inc., representing 0.10% of the company. Other institutional investors have also increased their positions in MBX. Despite missing earnings estimates for the recent quarter, analysts generally maintain a "Moderate …

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages

IDEAYA Biosciences (NASDAQ:IDYA) has received an average rating of "Moderate Buy" from sixteen brokerages, with an average 12-month price target of $50.13, significantly above its current share price of $36.30. The company's recent quarterly results showed revenue exceeding expectations but missed on earnings per …

Connect Biopharma (NASDAQ:CNTB) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen has upgraded Connect Biopharma (NASDAQ:CNTB) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with an average price target of $7.43. The company recently reported a quarterly loss of $0.27 per share, outperforming expectations, …

T. Rowe Price Associates (TWST) discloses 3.63M-share Twist Bioscience position

T. Rowe Price Associates has reported a beneficial ownership of 3,634,470 shares of Twist Bioscience Corp. (TWST), representing a 5.8% stake in the company's common stock. The firm holds sole voting power over 3,520,536 shares and sole dispositive power over all 3,634,470 shares, as …

Should Arcutis Biotherapeutics’ (ARQT) Strong Q2 and Higher 2026 Sales Outlook Prompt Investor Action?

Kyntra Bio Confronts Nasdaq Listing Risk as Asset and Revenue Shortfall Threatens Global Select Status

Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen

Wall Street Zen upgraded Puma Biotechnology (NASDAQ:PBYI) from a "buy" to a "strong-buy" rating, despite the broader analyst consensus remaining "hold" with a $6.00 price target. The company reported strong quarterly earnings, beating EPS and revenue estimates, though insiders have sold a significant number …

iBio (NASDAQ:IBIO) Rating Increased to Hold at Wall Street Zen

Wall Street Zen has upgraded iBio (NASDAQ:IBIO) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Buy" with a $5.00 average price target. The company recently reported a quarterly loss of $0.07 per share, missing estimates, and its stock …

Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold

Wall Street Zen has upgraded Vor Biopharma (NASDAQ:VOR) from a "sell" to a "hold" rating. Despite this, the overall analyst consensus for Vor Biopharma remains a "Moderate Buy" with an average price target of $43.38, though the company's stock trades significantly below its 52-week …

IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen downgraded IDEAYA Biosciences (NASDAQ:IDYA) from "hold" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $50.12. The company's shares opened at $36.30, and it recently reported a quarterly loss of $1.22 per share, …

Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded Arbutus Biopharma (NASDAQ:ABUS) from a "buy" to a "hold" rating, though Weiss Ratings simultaneously upgraded it from "sell" to "hold." The biopharmaceutical company holds a consensus "Moderate Buy" rating and a $5.00 price target. Despite missing quarterly EPS estimates by …

Maxim Group Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8

Maxim Group has reiterated its Buy rating for Palisade Bio (PALI.US) and maintained its target price at $8. This indicates continued confidence from the firm in the company's prospects.

Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded Upstream Bio (NASDAQ:UPB) to a "Strong Sell" rating from "Sell," intensifying cautious sentiment around the clinical-stage biotech company. Despite the downgrade, analyst opinions remain mixed, with four "Buy" ratings, two "Hold," and one "Sell," resulting in a consensus "Hold" …

Ajooni Biotech standalone net profit declines 44.87% in the June 2026 quarter

How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares

BioCryst Pharmaceuticals reported a significant profit swing in Q2 2026, with revenue of US$218.25 million and net income of US$78.4 million, prompting a raised full-year revenue outlook to US$690 million–US$715 million. Despite this strong quarter, the company still faces a substantial year-to-date net loss …

Annovis Bio (ANVS) posts $32.4M loss and warns on going-concern risk

Annovis Bio reported a six-month net loss of $32.4 million, primarily due to increased research and development expenses for its Alzheimer's and Parkinson's disease clinical trials. The company's cash and cash equivalents stood at $18.7 million, with management warning that these funds are only …

Gufic BioSciences consolidated net profit rises 70.70% in the June 2026 quarter

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook

Vor Biopharma (VOR) sees Frazier Life Sciences entities report under 5% ownership

Frazier Life Sciences-affiliated funds have filed an amended Schedule 13G indicating beneficial ownership of less than 5% of Vor Biopharma Inc. common stock. Frazier Life Sciences Public Fund, L.P. holds 4.2% of the class, while Frazier Life Sciences XII, L.P. holds 0.5%, and Frazier …

Why (ATRA) Price Action Is Critical for Tactical Trading

This article analyzes Atara Biotherapeutics Inc. (NASDAQ: ATRA) for tactical trading, highlighting a strong near and mid-term sentiment despite a weak long-term outlook. It identifies an exceptional 234.0:1 risk-reward setup targeting a 70.2% gain against 0.3% risk. The analysis also provides specific institutional trading …